Overproduction of genetically engineered antibodies, such as single-chain antibodies (scAbs) in
INTRODUCTION
Genetically engineered antibodies and their fragments produced in Escherichia coli have a great potential as specific targeting reagents, both in scientific research and clinical trials (1, 2) . There has been growing interest especially in the single-chain antibody (scAb) format of engineered antibodies, particularly for in vivo diagnostic and therapeutic applications because of its small size. However, one major factor that can limit the applicability of scAbs is the ability to produce them in large amounts as soluble and functional proteins. Actually, scAbs are often prone to form insoluble aggregates known as inclusion bodies when expressed in E. coli, especially at high level, resulting in low active yields. Although the expression of proteins as inclusion bodies leads to larger amounts of target proteins, the production of biologically functional products is stymied by the laborious procedures (3, 4) . Many strategies have been proposed to obtain improved solubility in the past years (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . However, the application of signal sequences or different culture conditions to a variety of engineered antibodies within our laboratory has met with little success (15) . Therefore, as the optimization of engineered antibody expression still tends to proceed on a case-by-case basis, a generic system is desirable to improve engineered antibody expression as soluble and active products in E. coli.
FkpA, a periplasmic peptidyl-prolyl cis, trans-isomerase (16) , is one of the heat shock proteins that are inducible in response to accumulation of misfolded proteins in E. coli (16) (17) (18) . Missiakas et al. found that FkpA decreased the sigma E-dependent response constitutively induced by misfolded proteins and proposed that FkpA plays an active role either as a folding catalyst or as a chaperone in E. coli (18) . Further investigation showed that FkpA has two activities, the cis, trans-isomerase activity and the chaperone-like activity (19) (20) (21) . A poorly folded single-chain variable fragment (scFv) displayed on filamentous phage and a defectivefolding variant of the maltose-binding protein, MalE31, were produced in biologically active form in E. coli functionally assisted by co-expression of FkpA (21, 22) .
Because all the engineered antibodies constructed in our laboratory were insoluble when expressed in E. coli, we sought to identify whether overexpression of FkpA would be of benefit to the expression of engineered antibodies of interest as soluble and functional forms. We have constructed various vectors for the fusion expression or co-expression of FkpA with engineered antibodies anti-human bladder carcinoma scAb (PG) and its fusion protein cellulose-binding domain from Cellulomonas fimi (CBD)-PG, anti-human CD3×anti-human ovarian carcinomabispecific scAb (BH1), and anti-human CD3×anti-human CD28×anti-human ovarian carcinoma-trispecific scAb (TRI). Our results demonstrate conclusively that fusion expression or co-expression of FkpA is sufficient for soluble and functional expression of engineered antibodies in E. coli.
Production of soluble and functional engineered antibodies in Escherichia coli improved by FkpA

MATERIALS AND METHODS
Reagents
Mouse anti-c-myc monoclonal antibody (cell line 9E10) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Goat anti-mouse immunoglobulin G horseradish peroxidase (IgG-HRP) and protein markers were purchased from Sino-American Biotechnology Company (Beijing, China). Anti-CD3 monoclonal antibody was purchased from Wuhan Institute of Biological Products (Wuhan, China). Anti-CD28 monoclonal antibody and rhCD28/FcChimera, recombinant human CD28 extracellular domain fused to human IgG 1 Fc, were products of R&D System (Minneapolis, MN, USA). Anti-ovarian carcinoma scFv was prepared by renaturing and purifying the inclusion body expressed in E. coli. Restriction endonucleases, T 4 DNA ligase, LA Taq DNA polymerase, and other modification enzymes were purchased from TaKaRa Biotechnology (Dalian), Ltd. (Dalian, China). pfu DNA polymerase was a product of Bioasia Company (Shanghai, China). Prestained protein markers were purchased from New England Biolabs (Beverly, MA, USA).
Human bladder carcinoma cell line BIU87, human ovarian carcinoma cell line SKOV3, and human T lymphoma cell line Jurkat, on the surface of which CD3 was overexpressed, were from our laboratory.
MTT was purchased from Sigma (St. Louis, MO, USA). All other chemicals were of analytical grade.
Bacterial Strains and Plasmids
E. coli DH5α and Top10 were used as the host strains for cloning and maintenance of plasmids throughout the experiments. E. coli BL21 Star (DE3) was purchased from Invitrogen (Carlsbad, CA, USA) and used as the host for expression of all the T7 promoter-based vectors constructed in this study.
The plasmid pTMF was constructed in our laboratory (15) and used as the basic vector for construction of all the expression plasmids in this study. The plasmid pTCM, constructed previously by inserting the complete coding sequence of c-myc (33 bp) into the multicloning site of pTMF (15) , was used as a control in ELISA of expressed target proteins against specific antigens. Plasmids pTP1 (15) and pTBNP1 (unpublished) were constructed previously and used for expression of PG and its fusion protein CBD-PG. Plasmids pALMBH1 and pTTRI were constructed in our laboratory (unpublished data) and used for expression of BH1 and TRI, respectively. All plasmids constructed and used in this study were diagrammatically shown in Figure 1 and summarized in Table 1 .
For the facile detection of the expressed scAbs against specific antigens, the C terminus of each of the scAbs mentioned in this study contains a c-myc tag, which can be detected by mouse anti-c-myc monoclonal antibody.
Isolation of the fkpA Open Reading Frame
fkpA genes [complete coding sequence with or without a ribosome binding site (RBS)] were isolated by PCR with pfu polymerase, using E. coli strain K12 chromosomal DNA as templates. The complete fkpA was amplified as follows: the forward primer was 5′-AAATCACTGTTTAAAGTA-ACG-3′. The reverse primer, 5′-GC-GAGCTCTTTTTTAGCAGAATCT-GCGG-3′, was designed to contain a SacI site (underlined). The PCR product was digested with SacI, purified, and cloned into the NcoI (blunted by the Klenow fragment of E. coli DNA polymerase I)-SacI site of pTMF, yielding plasmid pTFA ( Figure 1 ). Similarly, rbs-fkpA was amplified using the following primers. The forward primer was 5′-GAATGGCATATGAATAATT-TTGTTTAACTTTAAGAAGGAGA-TATATCCATGAAATCACTGTTTAA-AGTAAC-3′ and was designed to contain a NdeI site (underlined) and an RBS site (bolded). The reverse primer was 5′-GCGGATCCTTATTTTTTAG-CAGAATCTGC-3′ containing a BamHI site (underlined). The PCR product was digested with NdeI and BamHI, purified, and cloned into the same sites of pTMF, yielding pRFA ( Figure 1) .
The sequences of all the amplified genes were verified by DNA sequencing.
Construction of the FkpA Fusion and Co-Expression Vectors
For construction of the FkpA-PG fusion vector, the BglII-SacI fragment of pTFA was inserted into the BglII-SacI site of pTP1 to yield pTFP1. For construction of FkpA-BH1 fusion vector, the bispecific scAb BH1 was cloned from plasmid pALMBH1 by PCR using specific primers. The forward primer was 5′-CCGCTCGAGGTGCAGCTG-CAGGAGTCTGG-3′ designed to contain an XhoI site (underlined), and the reverse primer was 5′-TTACTGCAGT-TATCAGTTCAGGTCTTCTTCAG-3′. pfu polymerase was used in the PCR, and the products were recovered, digested with XhoI, and ligated into the XhoI-NdeI (blunted by the Klenow fragment of E. coli DNA polymerase I) site of pTFA to yield pTFBH1.
For construction of FkpA co-expression vector to co-express CBD-PG, the BglII-XhoI fragment of pTBNP1 was inserted into the BglII-XhoI site of pTRFA, and the resulting plasmid was designated pTBNP1F and used to co-express FkpA with fusion protein CBD-PG. For construction of FkpA co-expression vector to co-express trispecific scAb TRI, two specific primers were used to isolate the trispecific scAb gene by PCR from plasmid pTRI, which was constructed previously (Song et al., unpublished). The forward primer was 5′-CATCACCATCACCATCACCC-GTGCCGTCCATGTACTCAC-3′, and the reverse primer was 5′-TTAC-GGGCAAGGTGGACAAGT-3′.
To ensure the efficiency of PCR in cloning the long fragment TRI, LA Tag DNA polymerase was used. The PCR product was recovered and ligated into the NcoI site (blunted by the Klenow fragment of E. coli DNA polymerase I) of pTRFA. The resulting plasmid was designated pTTRIF. Each subset of the genes obtained above was placed under the control of the T7 promoter and the lac operator on pTMF-based vectors. The sequences of all the amplified genes were verified by DNA sequencing. All the pTMF-based vectors constructed in this study are diagramed in Figure 1 .
Culture Conditions, Protein Expression, and Analysis
All the expression plasmids were used to transform E. coli BL21 Star (DE3). BL21 Star (DE3) transformed cells were grown in LB medium (23) supplemented with antibiotics. Cultures were induced at an A 600 = 0.8 using 0.4 mM isopropyl-β-D-thiogalactopyranoside (IPTG). Typically, after several hours of induction, the induced cells from 1 mL of culture broth were harvested by centrifugation, resuspended in phosphate-buffered saline (PBS), and then treated by sonication. After centrifugation at 8000× g for 10 min at 4°C, the supernatant was taken as soluble fraction. The pellet was taken as insoluble fraction and resuspended in PBS. If needed, whole-cell proteins were prepared separately by harvesting 1 mL of culture broth directly with centrifugation. Thirty microliters of each of the above fractions and the wholecell proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), followed by visualization with Coomassie ® Brilliant Blue staining, and scanning quantitative analysis by spot density using the marker proteins as control.
ELISA for scFvs Activity and Western Blot Analysis
ELISAs were carried out in order to evaluate the antigen-binding activities of the soluble engineered antibodies PG, BH1, and TRI expressed in E. coli under the assistance of FkpA. Membrane antigens of BIU87 cells, Jurkat cells and SKOV3 cells, and CD28 pure antigen (rhCD28/FcChimera) were diluted in 0.1 M NaCO 3 -NaHCO 3 buffer, pH 9.6, and the final concentration of each antigen was adjusted to 10 µg/ mL. ELISA plates (NUNC, Roskilde, Denmark) were coated overnight at 4°C with each of the above membrane antigens, respectively. After washing three times with PBS with Tween ® 20 (PBST) and three times with PBS, the plates were blocked for 2 h at 37°C with 200 µL of 1% bovine serum albumin (BSA)-PBS and then washed with PBST and PBS, respectively. A total of 100 µL supernatant containing expressed target proteins (PG, BH1, or TRI) was applied to the blocked ELISA wells and incubated for 2 h at 37°C. PBS or supernatants from E. coli cells harboring empty vector pTMF or pTCM as negative controls, were also RESEARCH REPORT added and incubated for 2 h at 37°C. After the plates were washed, 100 µL mouse anti-c-myc monoclonal antibody were added and incubated for 1 h at 37°C. For detection, 100 µL of goat anti-mouse IgG-HRP antibody were used and incubated for another 1 h at 37°C. The development was carried out with a total of 100 µL o-phenylenediamine (OPD) solution (6 mg/mL OPD, 1% H 2 O 2 ) for 15-20 min at room temperature, and signals were read at 490 nm with Universal Microplate Reader Elx800 (Bio-Tek Instruments, Winooski, VT, USA) after stopping the reaction with 50 µL 2 M H 2 SO 4 .
Immunodetection by Western blot analysis was performed as described (23) . Briefly, proteins from sonication supernatants were subjected to SDS-PAGE (12% polyacrylamide gel). Prestained protein markers were used as the standard. Electrotransfer of proteins to nitrocellulose filters (0.45 µm; Pall-Gelman Sciences, Ann Arbor, MI, USA) was performed in the transfer buffer (39 mM glycine, 40 mM Tris-base, 0.03% SDS, 20% methanol) by using Hoefer™ TE 22 Mighty Small Transphor Tank Transfer Unit (Amersham Biosciences, Piscataway, NJ, USA) at constant current 400 mA for 1 h, and then the filter was blocked with 2% low-fat dry milk in TBS (TBS: 100 mol/L Tris-HCL, pH 7.5, 0.9% NaCl) at room temperature for about 1 h. Then the filter was washed with TBST (TBS containing 0.1% Tween 20) . Mouse anti-c-myc monoclonal antibody was added, and the filter was incubated for 1 h at room temperature. Next, goat anti-mouse IgG-HRP antibody was added, and the filter was incubated for another hour at room temperature. The peroxidase activity was developed with a solution of diaminobenzidine (DAB; 0.6 mg/mL) in 20 mM Tris-base, 0.5 M NaCl-buffered saline, and 0.1% H 2 O 2 .
In Vitro Cytotoxicity Assay for Trispecific scAb Co-Expressed with FkpA
Human peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated using Ficoll ® density gradient centrifugation, and monocytes/macrophages were depleted using glass adherence incubated at 37°C, 5% CO 2 for 2 h. A 96-well flatbottom plate was coated with target tumor cells SKOV3 and incubated overnight to prepare cell monolayers. The effector cells (PMBCs) were added to the tumor cell monolayers at the appropriate effector cells/tumor cells (E/T) ratios. Different dilutions of supernatants containing TRI were added to the plate, and then the plate was incubated at 37°C, 5% CO 2 for 72 h. After PBMCs were removed by washing, MTT solution (0.5 mg/mL) was added, and the plate was incubated for another 4 h. The MTT solution was then removed, and the crystals of formazan were dissolved in dimethyl sulfoxide (DMSO) at room temperature. The results were calculated based on the means of absorbance obtained from three wells according to the following formula:
where C is the absorbance reading of the cells with target cells (control), B is the background, and E is the absorbance reading of adherence tumor cells remaining in the wells after co-incubation with PBMCs (24) .
RESULTS
PG, CBD-PG, BH1, and TRI Always Aggregate as Inclusion Bodies When Expressed in E. coli
Although the induction conditions were optimized for efficient expression of the scAbs constructed in our laboratory, scAb PG and its fusion protein CBD-PG were totally insoluble in E. coli BL21 Star (DE3) (Figure 2A) . For facilitating the secretion of expressed proteins, the mature pg gene was fused to a signal peptide stII (a signal peptide from E. coli thermostable enterotoxinII) (25) or CBD (26) , which contains a pow- RESEARCH REPORT erful signal peptide, to yield expression vector pTP1 (15) and pTBNP1 (unpublished). However, no soluble products were observed as shown in Figure 2 . Under the same conditions as mentioned above, the expressed BH1 existed as inclusion bodies (data not shown), and most of the expressed TRI existed as insoluble form (see Figure 4A) .
Effects of FkpA Fusion or Co-Expression on the Soluble Production of Engineered Antibodies in E. coli
To achieve large amounts of soluble and biologically active scAbs, the FkpA-based fusion and co-expression vectors pTFP1, pTFBH1, pTBNP1F, and pTTRIF were constructed. In contrast to separate expression, most part of each scAb or its fusion protein FkpA-PG, FkpA-BH1, CBD-PG, or TRI was soluble after sonication of the whole cells analyzed by SDS-PAGE ( Figures 2B, 3A, and 4A) , and the soluble portion of FkpA-PG, FkpA-BH1, or CBD-PG accounts for 50%, 70%, . OCCD3CD28: anti-ovarian scAb, anti-CD3 monoclonal antibody, and anti-CD28 monoclonal antibody were used simultaneously as positive control; OCCD3: anti-ovarian scAb and anti-CD3 monoclonal antibody were used simultaneously; control: RPM1640 culture medium was used as negative control; TRI: the sonication supernatant of E. coli cells carrying pTTRIF was used to evaluate the in vitro cytotoxicity of TRI co-expressed with FkpA; pTMF: the sonication supernatant of E. coli cells harboring empty vector pTMF was used as a control. scAb, single-chain antibody; TRI, anti-human CD3×anti-human CD28×anti-human ovarian carcinoma-trispecific scAb.
and 81% of the total amount of each target protein, respectively, expressed at 37°C (Table 2) .
ELISA and Western Blot Analysis Results for scAbs
The ultimate object of FkpA-assisted expression of scAbs is to achieve biologically active products. Therefore, the antigen-binding activities of soluble FkpA-PG, FkpA-BH1, CBD-PG, and TRI, with their specific membrane antigens at different concentrations, were assayed by ELISA, and the results are shown in Figures 2C, 3B , and 4B and C, respectively. These results demonstrate that the soluble FkpA-PG, FkpA-BH1, CBD-PG, and TRI have relatively high binding affinities for their specific antigens, and the binding of the soluble target proteins with their respective antigens is specific. The immunoblotting results of the soluble TRI from co-expression with FkpA are shown in Figure 4A .
In Vitro Cytotoxicity for Trispecific scAb TRI Co-Expressed with FkpA
All the scAbs constructed previously in our laboratory were against various human carcinomas. Therefore, the in vitro cytotoxicity test is one of the most valuable evaluations. In this study, TRI-mediated in vitro cytotoxicity was measured by a colorimetric MTT-based assay, and the results are shown in Figure 4D . Varying E/T ratios were carried out with a constant amount of 60 µg/mL of sonication supernatant containing TRI. Anti-human ovarian carcinoma scAb, anti-CD3 monoclonal antibody, and anti-CD28 monoclonal antibody were used as controls. In addition, 60 µg/mL of sonication supernatant of E. coli cells harboring empty vector pTMF and PBS were used as negative controls. These in vitro cytotoxicity tests indicate that scAb TRI co-expressed with FkpA is biologically functional in vitro.
DISCUSSION
In the present work, we constructed a series of plasmids for induced expression of FkpA to assess the effects of fusion and/or co-expression on soluble and functionally active production of scAbs and their fusion proteins in E. coli. Our results demonstrated that FkpA is very effective for producing soluble and functional engineered antibodies in E. coli. Many attempts to improve functional expression of heterologous proteins by overexpression with folding catalysts were carried out, but only limited success was reported (27) (28) (29) . We previously tested the effects of E. coli Dsb proteins, a group of disulfide-forming proteins with chaperone activities, on soluble and functional expression of scAbs in E. coli and obtained excellent results (15) .
As described in the Results section, a substantial portion of each fusion protein FkpA-PG, CBD-PG, FkpA-BH1, or TRI in E. coli was soluble and functionally active. In all ELISAs, the antigen-binding affinities of each tested scAb or its fusion protein were much higher than those of controls used. Very promisingly, the in vitro cytotoxicity assay revealed that the trispecific scAb TRI folding assisted by FkpA was able to efficiently mediate the cell lysis against specific tumor cells. Our results clearly indicate that the scAbs overexpressed with FkpA are not only soluble but also biologically active in vitro. FkpA fused to or co-expressed with scAbs provides enough molecular activity and isomerase activity for the correct folding of target proteins of interest. Therefore, it is presumed that FkpA is the main factor leading to the change of scAbs from the insoluble forms to soluble forms when expressed in E. coli. The overproduced FkpA is most likely to efficiently enhance the correct folding by preventing aggregation of folding intermediates into inclusion bodies, thus yielding correctly folded proteins. There have been reports on demonstrating the chaperone-like activity of FkpA (21) . The chaperone-like activity of FkpA is probably responsible for the functional production of scAbs as a crucial factor. It is well known that some essential steps, such as the formation of correct configuration, the formation and isomerization of disulfide bonds, and the peptidyl-prolyl cis, trans isomerization, are involved in the production of functional scAbs in vivo. Actually, all the tested antibodies in our work contain several proline residues. Therefore, we proposed that the enzymatic activities of FkpA identified and still unidentified are also indispensable for the expression of biologically active scabs, since all the tested scAbs retained full antigen-binding affinities for their respective antigens and are able to kill specific tumor cells through in vitro BH1, anti-human CD3×anti-human ovarian carcinoma-bispecific scA; CBD, cellulose-binding domain from Cellulomonas fimi; PG, anti-human bladder carcinoma scAb; scAb, single-chain antibody; TRI, anti-human CD3×anti-human CD28×anti-human ovarian carcinoma-trispecific scAb.
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cytotoxicity. In our previous work, we tested extensively the effects of the general molecular chaperones GroEL/ GroES, the excellent fusion expression partners glutathione-S-transferase (GST) and thioredoxin, and the disulfide bond-forming related proteins DsbC and DsbG, on functional production of scAbs (15) . Only DsbC and DsbG markedly enhanced the soluble and functional expression of scAbs, most probably due to their enzymatic activities as well as chaperone-like activities. In addition, high-level expression of FkpA and its fusion proteins with scAbs are not detrimental to the host cells in our experiments, suggesting that expression systems based on FkpA are applicable as well as sufficient for assisted folding expression of scAbs in E. coli.
In this report, we have described the expression with high efficiency and the marked increase of protein solubilization by overproduction of FkpA under standard culture conditions. The successful use of FkpA for the soluble and functional expression of engineered antibodies should be useful for the development of strategies for the efficient production of recombinant proteins, in general, in soluble and functional form in E. coli.
